Aptevo More Than Doubles After Favorable Results in Leukemia Study

Aptevo Therapeutics' shares surged 114% to $6.03 after announcing positive results from a Phase 1b/2 trial of its mipletamig triplet therapy for acute myeloid leukemia (AML), showing 85% remission in evaluable frontline patients. The company also announced an $8 million registered direct offering at $3.25 per share and warrants, alongside a previously reported $25 million standby equity-purchase agreement with Yorkville Advisors.

Analysis

Aptevo Therapeutics (APVO) shares experienced a dramatic rebound, surging 114% to $6.03, after the company announced favorable Phase 1b/2 trial results for its lead drug candidate, mipletamig, in acute myeloid leukemia (AML). The mipletamig triplet therapy demonstrated an 85% remission rate in evaluable frontline AML patients unfit for intensive chemotherapy, with no dose-limiting toxicities observed. This positive clinical news, which led to trading volume exceeding 115 million shares against a 65-day average of approximately 275,000, contrasts with the stock's 52-week low of $2.81 reached just a day prior and its significant year-to-date decline of about 93%. Concurrently, Aptevo disclosed an $8 million registered direct offering, agreeing to sell shares or pre-funded warrants at $3.25 each, accompanied by substantial warrant issuance, a price considerably below the post-surge trading level. This financing follows a recently reported standby equity-purchase agreement with Yorkville Advisors for up to $25 million, signaling ongoing efforts to secure capital for operations and continued development.

Key Decisions for Investors

• Investors should balance the highly encouraging clinical data for mipletamig, which significantly de-risks its development pathway, with the dilutive effects of the $8 million registered direct offering priced at $3.25 per share and the existing $25 million standby equity facility.
• The substantial discount of the offering price compared to the recent market price, coupled with the stock's extreme volatility and severe year-to-date underperformance, necessitates a cautious assessment of the company's capital structure and future funding requirements.
• Monitor Aptevo's progress in advancing mipletamig through further clinical trials, its cash burn rate, and the terms of any future financing activities, as these will be critical determinants of sustained shareholder value.